Abstract
Cancer immunotherapy, including immune checkpoint inhibitors, exerts beneficial effects in cancer patients. However, immune checkpoint inhibitors are only advantageous for a limited population of cancer patients. Therefore, companion diagnostics are needed in order to identify patients for whom these therapies are effective. In the present study, we evaluated detailed immunological aspects in clinical specimens from non-small cell lung cancer (NSCLC) patients. We analyzed the immune profiles, T cell cytotoxicity, and TCR repertoire of peripheral blood, normal lung tissue, and tumor tissue from NSCLC patients. By using bispecific T-cell engager technology to assess the cytotoxicity of T cells, we found that the cytotoxicity of tumor-infiltrated T cells closely correlated with that of peripheral T cells. This correlation was supported by the immune profiles, cytokine production, and results of the TCR repertoire analysis from these specimens. We also found that the cytotoxicity of peripheral T cells has potential as a predictor of the effects of nivolumab in the tumor microenvironment. These results imply further applications to blood-based immune monitoring systems and predictive biomarkers for cancer immunotherapy.
References
Aug 1, 1997·Human Immunology·T MatsutaniR Suzuki
Feb 12, 2004·Cancer Research·Christian BlankThomas F Gajewski
Jan 24, 2007·Molecular Immunology·Melissa M DamschroderHerren Wu
Aug 16, 2008·Science·Ralf BargouPeter Kufer
Jun 11, 2009·Cancer Research·Patrick A Baeuerle, Carsten Reinhardt
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Chunlin WangJian Han
Apr 9, 2013·Future Oncology·Alessandro SattaMariangela Figini
Nov 19, 2013·Nature Immunology·Taku OkazakiTasuku Honjo
Aug 22, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kota IwahoriStephen Gottschalk
Mar 15, 2015·Science·Naiyer A RizviTimothy A Chan
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Feb 24, 2016·Nature Medicine·Alena GrosSteven A Rosenberg
Mar 31, 2016·The Oncologist·Joohee SulRichard Pazdur
Apr 9, 2016·Oncoimmunology·Jens SchreinerAlfred Zippelius
Jun 5, 2016·Proceedings of the National Academy of Sciences of the United States of America·Jennifer S SimsJeffrey N Bruce
Jun 5, 2016·Cancer Immunology Research·Michael J McNamaraWilliam L Redmond
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerMatthew D Hellmann
Oct 5, 2016·JCI Insight·Patrick H LizotteKwok-Kin Wong
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Apr 12, 2017·Nature·Alexander C HuangE John Wherry
Jun 28, 2017·Nature Reviews. Clinical Oncology·Mizuki NishinoF Stephen Hodi
Citations
Jul 7, 2019·Cancers·Takehiro OtoshiYoshihiro Nishimura
Mar 7, 2020·Scientific Reports·Yoko YamamotoHisashi Wada
Apr 23, 2020·Frontiers in Pharmacology·Luisa Chocarro de ErausoDavid Escors
Apr 5, 2020·International Journal of Molecular Sciences·Woan Ting TayPing-Yen Liu
Jul 8, 2020·Cancers·Magalie DossetMaurizio Zanetti
Sep 19, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Theresa A ProiaPatricia McCoon
Jan 16, 2021·Scientific Reports·Rodrigo Barbosa de AguiarJane Zveiter de Moraes
Jan 29, 2021·Cancers·Stéphane FattoriDaniel Olive
Feb 2, 2021·International Immunopharmacology·Annelieke E C A B WillemsenWinald R Gerritsen
Apr 3, 2021·Oncoimmunology·Jiaqi WangLin Feng
Jul 13, 2021·Frontiers in Oncology·Jin-Zhi LaiQiu-Yu Zhang
Jul 30, 2021·Scientific Reports·Sarah J DartSamantha E Bowyer
Sep 18, 2021·Frontiers in Immunology·Linlin WangYong Zeng
Oct 2, 2021·Science Immunology·Robert A WatsonBenjamin P Fairfax
Oct 2, 2021·Journal of the National Cancer Institute·Annette M MolinaroJennifer L Clarke